Mechanistic insights on the inhibition of tumor angiogenesis

Journal of Molecular Medicine

Volumn 78, Issue 12, 2001, Pages 663-672

  Jimenez B ^a   Volpert, O V ^b  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antiangiogenic factors; Endothelial cell apoptosis; Endothelial cell survival; Thrombospodin 1; Tumor angiogenesis

Indexed keywords

ANGIOGENESIS INHIBITOR; THROMBOSPONDIN;

ANGIOGENESIS; APOPTOSIS; CELL SURVIVAL; ENDOTHELIUM CELL; GENE CONTROL; GROWTH INHIBITION; HUMAN; MEDIATOR RELEASE; MESENCHYME CELL; MOLECULAR CLONING; NEOVASCULARIZATION (PATHOLOGY); REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; APOPTOSIS; CELL SURVIVAL; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; GENES, TUMOR SUPPRESSOR; GROWTH SUBSTANCES; HUMANS; LYMPHOKINES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034463222     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090000178     Document Type: Review

References (78)

1. Molecular mechanisms of vasculogenesis and embryonic angiogenesis
2. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells
3. Angiogenesis in cancer and other diseases
4. Tumour vascularity and proliferation: Clear evidence of a close relationship
5. The growth of malignant disease in man and lower animals with special reference to the vasculature system
6. Anti-angiogenesis: New concept for therapy of solid tumors
7. Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance
8. Tumor angiogenesis
9. How tumors become angiogenic
10. Factors promoting tumor angiogenesis
11. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases
12. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity
13. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
14. Complex role of matrix metalloproteinases in angiogenesis
15. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity
16. Angiogenesis-regulating cytokines: Activities and interactions
17. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo
18. Anti-angiogenic activity of prostate-specific antigen
19. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth
20. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin
21. Paracrine or virus-mediated induction of decorin expression by endothelial cells contributes to tube formation and prevention of apoptosis in collagen lattices
22. Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily
23. Brain-specific angiogenesis inhibitor 1 expression is inversely correlated with vascularity and distant metastasis of colorectal cancer
24. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity
25. Maspin is an angiogenesis inhibitor
26. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis
27. New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF
28. Thrombospondin as an inhibitor of angiogenesis
29. Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with dissordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis
30. Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls
31. Tumor angiogenesis: Past, present and the near future
32. Transgenic mouse models of tumour angiogenesis: The angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models
33. Establishing a link between oncogenes and tumor angiogenesis
34. Neoangiogenesis and relationship to nuclear p53 accumulation and vascular endothelial factor expression in advanced gastric carcinoma
35. Adenovirus-mediated wild type p53 gene transfer down-regulates vascular endothelial growth factor and inhibits angiogenesis in colon cancer
36. The Von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways
37. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by Von Hippel-Lindau tumor suppressor protein
38. Transforming growth factor beta is a target for the Von Hippel-Lindau tumor suppressor gene and a critical growth factor for clear cell renal carcinoma
39. Modulation of prostaglandin G/H synthase expression in mesangial cells transfected by p60c-src proto-oncogene
40. Fibronectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines. A process repressed through RAS/MAP kinase signaling pathways
41. Viral Myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1, a possible tumor suppressor gene
42. Myb-dependent regulation of thrombospondin 2 expression. Role of mRNA stability
43. The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun
44. Angiogenesis: How a tumor adapts to hypoxia
45. Critical role for cAMP response element binding protein expression on hypoxia-elicited induction of epithelial tumor necrosis factor-alpha
46. Cooperation between transcription factor AP-1 and NF-kappa B in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia
47. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1
48. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD
49. Multiple forms of angiostatin induce apoptosis in endothelial cells
50. Endostatin induces endothelial cell apoptosis
51. 2-Metoxyetsradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: Possible role for stress-activated protein kinase signaling pathway and Fas expression
52. Canstatin a novel matrix derived inhibitor of angiogenesis and tumor growth
53. Mechanisms of angiogenesis and arteriogenesis
54. Blood vessel maturation: Vascular development comes of age
55. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinipathy of prematurity
56. A plasticity window for blood vessel remodeling is defined by pericyte coverage of preformed endothelial network and is regulated by PDGF-B and VEGF
57. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor
58. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal
59. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
60. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
61. Vascular endothelial growth factor (VEGF) and its receptors
62. Tumor angiogenesis: Therapeutic implications
63. Review: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis
64. Vascular endothelial growth factor: Molecular and biological aspects
65. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
66. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
67. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway
68. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner
69. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial cell survival and angiogenesis
70. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells
71. Control of apoptosis during angiogenesis by survivin expression in endothelial cells
72. Marked induction of the IAP family of antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells
73. Integrins, angiogenesis and vascular cell survival
74. The role of integrins during angiogenesis: Insights into potential mechanisms of action and clinical development
75. αv integrins as receptors for tumor targeting by circulating ligands
76. Addressing tumor blood vessels
77. Chemotherapy targeted to tumor vasculature
78. Anti-cancer activity of targeted pro-apoptotic peptides